Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

UF startup Oragenics, Inc., a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, announced initial data from its ongoing Phase 2, placebo-controlled, clinical trial of AG013 in oral mucositis presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.

Alan Joslyn, President & CEO of Oragenics, Inc. said, “we are more than 75 percent enrolled in this study, and we continue to be encouraged by both the pace of enrollment and the overall clinical results as reported in this poster presentation. While it remains difficult to comment on efficacy outcomes based on these data, we are pleased with the safety profile we are seeing in the study. Due to the high incidence of SOM in head and neck cancer patients, and the blinded results seen to date, we maintain the belief that this compound will provide a convenient meaningful therapeutic benefit for these patients with limited treatment alternatives and no therapies available for prevention of their oral mucositis.”

Learn more about Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019.